EUVIMEDEUVIMED entdecken
Crossref

Ferroptosis suppression by MYC confers oxaliplatin resistance in colorectal cancer via FTH1 and GPX4

Yucheng Wang, Yulan Chen, Che Li, Jin Yang iD

Cancer Chemotherapy and Pharmacology · 06.08.2026 · 96 (1)

DOI: 10.1007/s00280-026-04936-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 06.08.2026. Verfasst von Yucheng Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences, Shanghai Normal University, Shanghai, 201418, China. Hauptthemen laut MEDLINE: Ferroptosis, Drug Resistance, Neoplasm, Colorectal Neoplasms, Proto-Oncogene Proteins c-myc. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Oxaliplatin resistance remains a major obstacle in the treatment of colorectal cancer (CRC). This study aimed to determine whether MYC contributes to oxaliplatin resistance by regulating ferroptosis and to clarify the downstream mechanisms involving FTH1 and GPX4. METHODS: Parental CRC cell lines, including HCT116, HT-29 and SW480, together with oxaliplatin-resistant HCT116-R cells, were used. MYC expression was manipulated by knockdown or overexpression. Oxaliplatin sensitivity was evaluated using CCK-8 assays and IC50 analysis. Intracellular Fe2⁺ and reactive oxygen species (ROS) levels were measured to assess ferroptosis-associated changes. RT-qPCR and western blotting were performed to examine gene and protein expression. Chromatin immunoprecipitation-qPCR and dual-luciferase reporter assays were used to investigate the transcriptional regulation of FTH1 and GPX4 by MYC. Rescue experiments with FTH1 or GPX4 overexpression and sorafenib treatment were also conducted. RESULTS: MYC knockdown significantly increased oxaliplatin sensitivity in both parental and resistant CRC cells and elevated intracellular Fe2⁺ and ROS levels. MYC directly bound to the promoter regions of FTH1 and GPX4 and enhanced their transcriptional activity. Downregulation of MYC reduced FTH1 and GPX4 expression, whereas re-expression of either FTH1 or GPX4 partially restored oxaliplatin resistance. Sorafenib further enhanced oxaliplatin sensitivity in resistant cells. CONCLUSION: MYC promotes oxaliplatin resistance in CRC cells, at least in part, by transcriptionally upregulating FTH1 and GPX4 and suppressing ferroptosis-associated cell death. The MYC-FTH1/GPX4-ferroptosis axis may represent a potential therapeutic target for overcoming oxaliplatin resistance in CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisDrug Resistance, NeoplasmColorectal NeoplasmsProto-Oncogene Proteins c-mycOxaliplatinPhospholipid Hydroperoxide Glutathione PeroxidaseAntineoplastic AgentsFerritinsOxidoreductasesHumansReactive Oxygen SpeciesCell Line, TumorGene Expression Regulation, NeoplasticHT29 CellsHCT116 Cells

Stichwörter der Autor:innen

ChemoresistanceFTH1FerroptosisGPX4MYC

Substanzen

Proto-Oncogene Proteins c-mycOxaliplatinPhospholipid Hydroperoxide Glutathione PeroxidaseMYC protein, humanFTH1 protein, humanReactive Oxygen SpeciesAntineoplastic AgentsFerritinsOxidoreductases

Autor:innen und Institutionen

  • College of Life Sciences, Shanghai Normal University, Shanghai, 201418, China.
  • Key Laboratory of Exploration and Utilization of Aquatic Genetic Resources, Ministry of Education, Shanghai Ocean University, Shanghai, 201306, China.
  • National Demonstration Center for Experimental Fisheries Science Education, Shanghai Ocean University, Shanghai, 201306, China.
  • College of Life Sciences, Shanghai Normal University, Shanghai, 201418, China. yangjin@shnu.edu.cn.

ORCID-Profile: Jin Yang

Zitieren

APA

Wang, Y., Chen, Y., Li, C., & Yang, J. (2026). Ferroptosis suppression by MYC confers oxaliplatin resistance in colorectal cancer via FTH1 and GPX4. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04936-3

Vancouver

Wang Y, Chen Y, Li C, Yang J. Ferroptosis suppression by MYC confers oxaliplatin resistance in colorectal cancer via FTH1 and GPX4. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04936-3

BibTeX
@article{Wang2026,
  author = {Wang, Yucheng and Chen, Yulan and Li, Che and Yang, Jin},
  title = {Ferroptosis suppression by MYC confers oxaliplatin resistance in colorectal cancer via FTH1 and GPX4},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2026},
  volume = {96},
  number = {1},
  doi = {10.1007/s00280-026-04936-3}
}
Kostenlos starten →